NCT05104736View on ClinicalTrials.gov

PT-112 in Subjects With Thymoma and Thymic Carcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

April 6, 2022

Primary Completion Date

December 31, 2026

Study Completion Date

June 30, 2027

Conditions
Thymic Epithelial TumorRecurrent ThymomaThymic Cancer
Interventions
DRUG

PT-112

PT-112 will be administered intravenously in 28-day cycles, on Days 1 and 15 at a dose of 360 mg/m2 for cycle 1, and on day 1 at 250mg/m2 for each subsequent cycle,

Trial Locations (1)

20892

RECRUITING

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH